why choose us

First received: September 06, 2022

Clinical Trial: Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis

Study Status: Completed

Recruit Status: RECRUITING

Condition: Myelofibrosis

Study Type: INTERVENTIONAL


Official Title: Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis (ATIOM)

Brief Summary: This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis.Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the Recommended Phase 2 Dose (RP2D).Once the RP2D is identified, 6 additional patients will be enrolled in the expansion cohort.

Read more